Aptar | |
Company type | Public |
Industry | Packaging and drug delivery devices |
Founded | 1992[1] |
Headquarters | , U.S. |
Key people | Stephan Tanda (CEO), Robert Kuhn (CFO), Shiela Vinczeller (CHRO) |
Products |
|
Revenue | US$3.487 billion (2023) |
$404 million [2] (2023) | |
$284 million [3] (2023) | |
Total assets | $4.451 billion [4] (2023) |
Total equity | US$2.321 billion [5] (2023) |
Number of employees | 13,800 (2023) [6] |
Subsidiaries |
|
Website | https://www.aptar.com/ |
AptarGroup, Inc., also known as Aptar, is a United States-based global manufacturer of consumer dispensing packaging and drug delivery devices. [7] [1] The group has manufacturing operations in 18 countries. [8]
The company began as Werner Die & Stamping in Cary, Illinois, in 1946 and later incorporated as AptarGroup in 1992. [1] [9] Aptar originally developed spray valves and pumps for consumer and household products. The company later began producing nasal administration and pulmonary drug delivery devices such as nasal spray systems and metered-dose inhaler valves. [9] [10] [11] [12] Biotech and pharmaceutical companies use Aptar's different Unidose and Bidose devices for the single or two-shot intranasal delivery of different medicines. [13]
In 2016, Aptar announced that it provided the delivery system for Adapt Pharma's Narcan. [14] Narcan is a naloxone hydrochloride nasal spray used as an emergency treatment for opioid overdoses. [14] Aptar's liquid spray drug delivery technology platform works as a ready-to-use, single-shot, unit-dose system for Narcan. It was the first FDA approved nasally administered, ready-to-use medication used to reverse the effects of an opioid overdose. [14] Narcan does not require any assembly, medical training, or needle injection. [15]
In 2016, Aptar entered into an agreement with Becton Dickinson & Company to develop new self-injection devices. [16] [17]
Aptar entered into an agreement in 2016 with Propeller Health Partners to develop a digitally connected medication inhaler. [18] The company made an investment in Propeller Health Partners (now part of Resmed) in 2018. [19]
In July 2019, the FDA-approved Aptar Pharma's Unidose Powder System as the first intranasally-delivered, needle-free rescue treatment for severe hypoglycemia. [13]
In 2020, during the COVID-19 pandemic, Aptar invested in new tools to accelerate its molding equipment and assembly machines for pumps, but it still wasn't enough to keep up with demand. [20]
In 2012, Aptar acquired Stelmi, a manufacturer of elastomer primary packaging components. [21] In 2016, Aptar acquired Mega Airless, a manufacturer of airless packaging solutions. [22] In 2018, Aptar acquired CSP Technologies, a material science company that manufactures active packaging solutions. [23]
In June 2019, Aptar acquired two companies, Nanopharm and Gateway Analytical. [24] In November 2019, the company acquired Noble International, which specializes in training devices and patient onboarding. [25] In February 2020, Aptar acquired FusionPKG, a makeup packaging company. [26] [27]
In November 2020, the company acquired the digital respiratory health company Cohero Health. [28] [29]
In July 2021 Aptar acquired the digital therapeutics company, Voluntis (ENXTPA: ALVTX), and 80% of the equity interests of Weihai Hengyu Medical Products Co., Ltd., a Chinese manufacturer of elastomeric and plastic components used in injectable drug delivery. [30]
Aptar was named to Barron's list of the Top 100 Most Sustainable U.S. Companies in 2019, 2020, 2021, and 2022. [31] [32] [33] [34] At the end of 2020, 85% of the company’s global electricity use came from renewable sources. [35] It was also named by Newsweek as one of America's Most Responsible Companies in 2021, [36] 2022, [37] and 2023 [38] and received an A score for climate change from the Climate Disclosure Project. [39]
In September 2019, the company announced a partnership with Loop, a shopping platform from TerraCycle that delivers products in reusable containers. [40] The company made the Forbes Green Growth 50 List in 2021. [41]
Fentanyl is a highly potent synthetic piperidine opioid primarily used as an analgesic. It is 20 to 40 times more potent than heroin and 100 times more potent than morphine; its primary clinical utility is in pain management for cancer patients and those recovering from painful surgeries. Fentanyl is also used as a sedative. Depending on the method of delivery, fentanyl can be very fast acting and ingesting a relatively small quantity can cause overdose. Fentanyl works by activating μ-opioid receptors. Fentanyl is sold under the brand names Actiq, Duragesic and Sublimaze, among others.
Naloxone, the active ingredient in Narcan, is an opioid antagonist: a medication used to reverse or reduce the effects of opioids. Naloxone is commonly used to restore breathing after an opioid overdose. Effects begin within two minutes when given intravenously, five minutes when injected into a muscle, and ten minutes as a nasal spray. Naloxone blocks the effects of opioids for 30 to 90 minutes.
In pharmacology and toxicology, a route of administration is the way by which a drug, fluid, poison, or other substance is taken into the body.
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.
Purdue Pharma L.P., formerly the Purdue Frederick Company (1892–2019), was an American privately held pharmaceutical company founded by John Purdue Gray. It was sold to Arthur, Mortimer, and Raymond Sackler in 1952, and then owned principally by the Sackler family and their descendants.
Nalmefene is a medication that is used in the treatment of opioid overdose and alcohol dependence. Nalmefene belongs to the class of opioid antagonists and can be taken by mouth, administered by injection, or delivered through nasal administration.
The Minneapolis Fire Department provides fire protection and first responder emergency medical services to the city of Minneapolis, Minnesota.
An opioid overdose is toxicity due to excessive consumption of opioids, such as morphine, codeine, heroin, fentanyl, tramadol, and methadone. This preventable pathology can be fatal if it leads to respiratory depression, a lethal condition that can cause hypoxia from slow and shallow breathing. Other symptoms include small pupils and unconsciousness; however, its onset can depend on the method of ingestion, the dosage and individual risk factors. Although there were over 110,000 deaths in 2017 due to opioids, individuals who survived also faced adverse complications, including permanent brain damage.
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
Orexo is a Swedish pharmaceutical company that develops improved pharmaceuticals based on innovative formulation technologies that meet large medical needs. Through presence its in the US market, drugs and digital therapies are commercialized to treat opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with partners.
Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.
Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.
There is an ongoing opioid epidemic in the United States, originating out of both medical prescriptions and illegal sources. The epidemic began in the United States in the late 1990s, according to the Centers for Disease Control and Prevention (CDC), when opioids were increasingly prescribed for pain management, resulting in a rise in overall opioid use throughout subsequent years.
Phil Skolnick is an American neuroscientist and pharmacologist most widely known for his work on the psychopharmacology of depression and anxiety, as well as on addiction medicine. Author of more than 500 published papers, Skolnick's most notable accomplishments include elucidating the role of the NMDA system in depression therapeutics, demonstrating the existence of endogenous benzodiazepine receptor ligands, and spearheading the National Institute on Drug Abuse's partnership to develop a naloxone atomizer for reversal of acute opioid overdose. Skolnick's work also laid the foundation for the development of ketamine as a rapid-acting antidepressant.
The opioid epidemic, also referred to as the opioid crisis, is the rapid increase in the overuse, misuse/abuse, and overdose deaths attributed either in part or in whole to the class of drugs called opiates/opioids since the 1990s. It includes the significant medical, social, psychological, demographic and economic consequences of the medical, non-medical, and recreational abuse of these medications.
Sean Scanlon is an American politician who is the current Comptroller of Connecticut. Scanlon previously served in the Connecticut House of Representatives from the 98th district.
Scott E. Hadland is a Canadian-American physician and scientist who serves as a pediatrician, and addiction specialist at Massachusetts General Hospital and Harvard Medical School, where he is the Chief of the Division of Adolescent and Young Adult Medicine. He previously served as an addiction specialist at the Grayken Center for Addiction at Boston Medical Center.
Harm reduction consists of a series of strategies aimed at reducing the negative impacts of drug use on users. It has been described as an alternative to the U.S.'s moral model and disease model of drug use and addiction. While the moral model treats drug use as a morally wrong action and the disease model treats it as a biological or genetic disease needing medical intervention, harm reduction takes a public health approach with a basis in pragmatism. Harm reduction provides an alternative to complete abstinence as a method for preventing and mitigating the negative consequences of drug use and addiction.
In response to the surging opioid prescription rates by health care providers that contributed to the opioid epidemic in the United States, US states began passing legislation to stifle high-risk prescribing practices. These new laws fell primarily into one of the following four categories: